Objective: Chemoradiation based on S-1, a novel oral antitumor agent of fluorinated pyrimidines, is the treatment for T2N0 glottic carcinoma; however, the optimal scheduling and dosing have still not been established. A phase I study was conducted to determine the maximum tolerated dose of S-1 with radiotherapy of 2 Gy/day for 5 days a week to a total dose of 60 Gy. Endpoints of this study were to examine the toxicity profile of this regimen and to determine the recommended dose of S-1. Methods: Concomitant administration with the above-mentioned radiotherapy of S-1 once a day for 2 weeks, beginning on the day therapy was started, followed by 2 weeks off the drug and 2 weeks on the drug with the dose escalating from S-1 60 mg/body (level 1) to 80 mg/body/day (level 2), and then to 100 mg/body/day (level 3). Results: Twenty-one patients were valid for safety. Eighteen patients were enrolled in the dose-escalation phase. In all patients, S-1 was administered. The maximum tolerated dose was determined to be 100 mg/body/day and the dose-limiting toxicity was indicated by the onset of grade 3 chemoradiation dermatitis. Therefore, the determined recommended dose of S-1 was 80 mg/body/day. Objective response according to Response Evaluation Criteria in Solid Tumors were observed in 20 of 21 patients who had measurable disease (95.2%). Conclusion: Concurrent S-1 and radiotherapy was feasible and well tolerated, and was suggested to produce a worthwhile response in T2N0 glottic carcinoma. These results warrant further investigation, and a phase II has already been started.

Keywords:
Phase I study, Chemoradiation, S-1, Head and neck cancer
1.
Piccirillo JF: Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593–602.
2.
Marcial VA, Pajak TF: Radiation therapy alone or in combination with surgery in head and neck cancer. Cancer 1985;55:2259–2265.
3.
Mendenhall WM, Werning JW, Hinerman RW, Amdur RJ, Villaret DB: Management of T1-T2 glottic carcinomas. Cancer 2004;100:1786–1792.
4.
Harada K, Kawaguchi S, Supriatno, Onoue T, Yoshida H, Sato M: Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells. Oral Oncol 2004;40:713–719.
5.
National Cancer Institute: National Cancer Institute Common Toxicity Criteria (version 2). Bethesda, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 1999.
6.
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–216.
7.
Cerezo L, Millan I, Torre A, Aragon G, Otero J: Prognostic factors for survival and tumor control in cervical lymph node metastases from head and neck cancer. A multivariate study of 492 cases. Cancer 1992;69:1224–1234.
8.
Snyder MC, Lydiatt WM, Lydiatt DD: Glottic cancer. 2006. http://www.emedicine.com/ent/topic688.htm.
9.
Yamazaki H, Nishiyama K, Tanaka E, Koizumi M, Chatani M: Radiotherapy for early glottic carcinoma (T1N0M0): results of prospective randomized study of radiation fraction size and overall treatment time. Int J Radiat Oncol Biol Phys 2006;64:77–82.
10.
Lo TC, Wiley AL Jr, Ansfield FJ, Brandenburg JH, Davis HL Jr, Gollin FF, Johnson RO, Ramirez G, Vermund H: Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: a randomized study. AJR Am J Roentgenol 1976;126:229–235.
11.
Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F: Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8:1923–1933.
12.
Sanchiz F, Milla A, Torner J, Bonet F, Artola N, Carreno L, Moya LM, Riera D, Ripol S, Cirera L: Single fraction per day versus two fractions per day versus radiochemotherapy in the treatment of head and neck cancer. Int J Radiat Oncol Biol Phys 1990;19:1347–1350.
13.
Fu KK, Phillips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, Friedman MA, Kohler M, McWhirter K, Carter SK: Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410–1418.
14.
Dobrowsky W, Naude J, Widder J, Dobrowsky E, Millesi W, Pavelka R, Grasl C, Reichel M: Continuous hyperfractionated accelerated radiotherapy with/without mitomycin C in head and neck cancer. Int J Radiat Oncol Biol Phys 1998;42:803–806.
15.
Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N: Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29–37.
16.
Jeremic B, Shibamoto Y, Milicic B, Nikolic N, Dagovic A, Aleksandrovic J, Vaskovic Z, Tadic L: Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol 2000;18:1458–1464.
17.
Browman GP, Hodson DI, Mackenzie RJ, Bestic N, Zuraw L; Cancer Care Ontario Practice Guideline Initiative Head and Neck Cancer Disease Site Group: Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: a systematic review of the published literature with subgroup analysis. Head Neck 2001;23:579–589.
18.
Adelstein DJ, Kalish LA, Adams GL, Wagner H Jr, Oken MM, Remick SC, Mansour EG, Haselow RE: Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: an Eastern Cooperative Oncology Group pilot study. J Clin Oncol 1993;11:2136–2142.
19.
Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, Al-Sarraf M: Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123–1128.
20.
Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni VC, Jirillo A, Tomio L, Fila G, Fede A, Endrizzi L, Bari M, Sampognaro E, Balli M, Gava A, Pappagallo GL, Fiorention MV: Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265–272.
21.
Athanasiadis I, Taylor S 4th, Vokes EE, Pelzer HJ, Rademaker A, Mittal BB, Ganzenko N, Blough R, Lester EP, Kies MS: Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck: a long-term analysis for the Illinois Cancer Center. Cancer 1997;79:588–594.
22.
Adelstein DJ: Induction chemotherapy in head and neck cancer. Hematol Oncol Clin North Am 1999;13:689–698.
23.
Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK: A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7–16.
24.
Fukushima M, Shimamoto Y, Kato T, Uchida J, Yonekura R, Ohshimo H, Shirasaka T: Anticancer activity and toxicity of S-1, an oral combination of tegafur and two biochemical modulators, compared with continuous i.v. infusion of 5-fluorouracil. Anticancer Drugs 1998;9:817–823.
25.
Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996;7:548–557.
26.
Inuyama Y, Kida A, Tsukuda M, Kohno N, Satake B; S-1 Cooperative Study Group (Head and Neck Cancer Working Group): Late phase II study of S-1 in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 2001;28:1381–1390.
27.
Ziras N, Tsoutsou P, Koliarakis N, Magdalinos N, Sarris G, Potamianou A, Paraskevaides M, Synodinou M, Chrysanthou K, Karageorgis P, Athanassiou AE: Phase I study of postoperative radiotherapy with concomitant weekly irinotecan, 5-fluorouracil and folinic acid in locally advanced rectal cancer. J BUON 2004;9:255–261.
© 2006 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.